Phase 3 TRIUMPH readouts show dose-dependent mean weight loss up to ~30% at 104 weeks in obesity and ~21% in T2D, with ...
Higher-performing Medicare accountable care organizations are smaller and characterized by real-time information sharing, ...
Obesity, MASH, and the Metabolic Dysfunction That Connects Them,' Jaime Almandoz, MD explores the following questions: As an endocrin ...
Following the Steward Health Care bankruptcy, Massachusetts law HB 5159 mandates rigorous oversight of for-profit health care ...
A large UK cohort study found atopic dermatitis raises the risk of shingles by 28%, with the steepest risk in severe disease ...
A narrative review found obesity independently worsens psoriasis severity and blunts response to fixed-dose biologics, ...
Brittany G. Craiglow, MD, FAAD, discusses JAK inhibitor hesitancy in pediatric alopecia areata, boxed warnings, and why step ...
The cereblon E3 ligase modulator, or CELMoD, also received a breakthrough therapy designation from the FDA. The FDA has granted an accelerated approval to the regimen ...
Forecasted cost growth was highest in fully insured arrangements, consistent with constrained data rights; only about 60% felt able to audit full claims files. Employers with complete claims data ...
The disparity in outcomes between pediatric and young adult patients with ALL is multifactorial, explained Emily K. Curran, MD.
Nationwide difference-in-differences analysis (IPTW-adjusted) compared 180-day preadmission vs 180-day postdischarge HEDIS ...
Setmelanotide produced a mean body mass index (BMI) reduction of 16.5% in patients with acquired hypothalamic obesity, compared with a 3.3% increase among those receiving placebo, according to trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results